Intellia Therapeutics Inc [NTLA] stock prices are down -3.69% to $24.52 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NTLA shares have gain 22.85% over the last week, with a monthly amount glided 114.71%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Intellia Therapeutics Inc [NASDAQ: NTLA] stock has seen the most recent analyst activity on October 06, 2025, when Citizens JMP upgraded its rating to a Mkt Outperform but kept the price target unchanged to $33 for it. Previously, Wolfe Research upgraded its rating to Outperform on April 21, 2025, and kept the price target unchanged to $21. On March 05, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $30 on the stock. JP Morgan downgraded its rating to a Neutral and decreased its price target to $13 on February 28, 2025. Goldman downgraded its rating to a Sell but $9 remained the price target by the analyst firm on February 28, 2025. Morgan Stanley downgraded its rating to Equal-Weight for this stock on January 27, 2025, and downed its price target to $11. In a note dated February 23, 2024, Goldman downgraded a Neutral rating on this stock and revised its target price from $136 to $32.
The stock price of Intellia Therapeutics Inc [NTLA] has been fluctuating between $5.90 and $26.99 over the past year. Currently, Wall Street analysts expect the stock to reach $23.5 within the next 12 months. Intellia Therapeutics Inc [NASDAQ: NTLA] shares were valued at $24.52 at the most recent close of the market. An investor can expect a potential drop of -4.16% based on the average NTLA price forecast.
Analyzing the NTLA fundamentals
The Intellia Therapeutics Inc [NASDAQ:NTLA] reported sales of 52.86M for trailing twelve months, representing a surge of 104.76%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -9.69%, Pretax Profit Margin comes in at -9.08%, and Net Profit Margin reading is -9.08%. To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -0.58 and Total Capital is -0.64. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Intellia Therapeutics Inc [NASDAQ:NTLA]’s Current Ratio is 5.19. Also, the Quick Ratio is 5.19, while the Cash Ratio stands at 1.64. Considering the valuation of this stock, the price to sales ratio is 49.79, the price to book ratio is 3.61.
Transactions by insiders
Recent insider trading involved Schultes Birgit C, EVP, Chief Scientific Officer, that happened on Oct 01 ’25 when 31.0 shares were sold. VP, Chief Accounting Officer, Dube Michael P completed a deal on Oct 01 ’25 to sell 1871.0 shares. Meanwhile, Director CHASE WILLIAM J bought 100000.0 shares on Aug 20 ’25.
